NG 1001, nanoencapsue formulation is in advanced preclinical testing, and has shown a non-toxicity profile, and promising inhibits growth of liver and prostate tumors in animal studies. NG1001 contains siRNA tumor suppressor and the nanoencapsule vector.
Clinical Trials
NABI
GENMED
NG 1003, nanoparticles gene drug is in preclinical studies, and has demonstrated a pronounced transfection efficiency of gene, and recognition to tumor cells of breast and cervix.
